# A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis

> **NCT07371793** · PHASE1,PHASE2 · RECRUITING · sponsor: **Bond Biosciences** · enrollment: 34 (estimated)

## Conditions studied

- Hereditary Hemochromatosis

## Interventions

- **DRUG:** BBI-001
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07371793
- **Lead sponsor:** Bond Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-04
- **Primary completion:** 2027-02
- **Final completion:** 2027-02
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07371793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07371793, "A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT07371793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*